Cellusion Company
Differentiation induction method to produce corneal endothelial substituted cells from iPS cells.
Technology:
Regenerative Medicine
Industry:
Cell Therapy
Headquarters:
Tokyo, Tokyo, Japan
Founded Date:
2015
Employees Number:
10-1
Investors Number:
4
Total Funding:
470000000
Last Funding Date:
43982
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership